Online inquiry

IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11607MR)

This product GTTS-WQ11607MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&IL3RA gene. The antibody can be applied in Acute myeloid leukemia (AML), Myelodysplastic syndromes (MDS) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Mus musculus; Humanized
RefSeq NM_000733.4; NM_001267713.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 3563
UniProt ID P07766; P26951
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11607MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2616MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 557
GTTS-WQ3896MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BCD-100
GTTS-WQ15889MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA XMT-1536
GTTS-WQ2789MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG-282
GTTS-WQ12272MR IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MRA
GTTS-WQ2543MR IVTScrip™ mRNA-Anti-GCGR, AMG 477(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 477
GTTS-WQ8362MR IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA hPAM4
GTTS-WQ15682MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA VB6-845
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW